These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2577106)

  • 21. [Alkylating tumor inhibitors--work mechenism and metabolism].
    Gescher A
    Pharm Unserer Zeit; 1976 Mar; 5(2):41-52. PubMed ID: 817296
    [No Abstract]   [Full Text] [Related]  

  • 22. Antitumour alkylating agents: cytotoxic action and organ toxicity.
    Connors TA
    IARC Sci Publ; 1986; (78):143-5. PubMed ID: 3583387
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of bone marrow homotransplantation on the toxicity and antineoplastic property of some alkylating agents].
    Veksler IG; Shevchenko VN
    Vopr Onkol; 1965; 11(7):71-6. PubMed ID: 4956684
    [No Abstract]   [Full Text] [Related]  

  • 24. Some pyrimidines of biological and medicinal interest. 3.
    Cheng CC; Roth B
    Prog Med Chem; 1971; 8(1):61-117. PubMed ID: 4935664
    [No Abstract]   [Full Text] [Related]  

  • 25. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents.
    Bodor N; Kaminski JJ
    J Med Chem; 1980 May; 23(5):566-9. PubMed ID: 7381858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell cycle effects of alkylating agents.
    Meyn RE; Murray D
    Pharmacol Ther; 1984; 24(2):147-63. PubMed ID: 6379683
    [No Abstract]   [Full Text] [Related]  

  • 27. The biology of alkylating-agent cellular injury.
    Shulman LN
    Hematol Oncol Clin North Am; 1993 Apr; 7(2):325-35. PubMed ID: 8468267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorescent alkylating agents. 1-(beta-chloroethyl)bisbenzimidazoles.
    Tsou KC; Rabiger DJ; Sobel B
    J Med Chem; 1969 Sep; 12(5):818-22. PubMed ID: 5812194
    [No Abstract]   [Full Text] [Related]  

  • 29. Antineoplastic activity of derivatives of phosphoric acid.
    Serebryanyi AM; Zoz NN; Semenova NA; Morozova IS; Kolotenkov PV; Babaev MS
    Biol Bull Acad Sci USSR; 1979; 6(4):497-8. PubMed ID: 549685
    [No Abstract]   [Full Text] [Related]  

  • 30. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.
    Frei E; Holden SA; Gonin R; Waxman DJ; Teicher BA
    Cancer Chemother Pharmacol; 1993; 33(2):113-22. PubMed ID: 8261570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of antitumor alkylating agents (AA).
    Teicher BA; Frei E
    Cancer Treat Res; 1991; 57():261-95. PubMed ID: 1686721
    [No Abstract]   [Full Text] [Related]  

  • 32. Conference on a new look at older drugs in cancer treatment: Project to Review Older Drugs (PROD). Sponsored by the Division of Cancer Treatment, National Cancer Institute, June 8-9, 1982, at the National Institutes of Health, Bethesda, Maryland.
    Med Pediatr Oncol; 1983; 11(6):383A-528B. PubMed ID: 6669143
    [No Abstract]   [Full Text] [Related]  

  • 33. Antineoplastic agents and the liver.
    Ménard DB; Gisselbrecht C; Marty M; Reyes F; Dhumeaux D
    Gastroenterology; 1980 Jan; 78(1):142-64. PubMed ID: 7350020
    [No Abstract]   [Full Text] [Related]  

  • 34. Selection of carriers for alkylating moieties to increase their antitumor specificity: a different aspect.
    Niculescu-Duvăz I; Baracu I
    Cancer Treat Rep; 1977 Aug; 61(5):929-31. PubMed ID: 890700
    [No Abstract]   [Full Text] [Related]  

  • 35. [Tumour chemotherapy. Syntheses of N-acetyl-N-(3-[bis-(beta-chloroethyl)-amino]-6-methyl-phenyl)-glycine and its demethyl analogues].
    Sun HL; Shen SY; Shu HL; Owen TY
    Yao Xue Xue Bao; 1965 Aug; 12(8):500-6. PubMed ID: 5899133
    [No Abstract]   [Full Text] [Related]  

  • 36. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticancer active illudins: recent developments of a potent alkylating compound class.
    Schobert R; Knauer S; Seibt S; Biersack B
    Curr Med Chem; 2011; 18(6):790-807. PubMed ID: 21182482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anticancer chemotherapy. I. Chemicals and action mechanisms].
    Amiel JL
    Nouv Presse Med; 1979 Apr; 8(19):1567-9. PubMed ID: 492974
    [No Abstract]   [Full Text] [Related]  

  • 40. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells.
    Denny WA; Wilson WR
    J Med Chem; 1986 Jun; 29(6):879-87. PubMed ID: 3712377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.